- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02223754
Evaluation of an Investigational Multifocal Lens
June 18, 2018 updated by: Johnson & Johnson Vision Care, Inc.
The purpose of this study is to test the performance of an investigational multifocal test soft contact lens.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
371
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Montgomery, Alabama, United States, 36109
-
-
California
-
Mission Viejo, California, United States, 92691
-
-
Florida
-
Jacksonville, Florida, United States, 32205
-
Jacksonville, Florida, United States, 32250
-
Orange Park, Florida, United States, 32065
-
Saint Augustine, Florida, United States, 32092
-
Tallahassee, Florida, United States, 32308
-
Tampa, Florida, United States, 33625
-
Winter Park, Florida, United States, 32792
-
-
Georgia
-
Roswell, Georgia, United States, 30076
-
-
Kansas
-
Pittsburg, Kansas, United States, 66762
-
-
Michigan
-
East Lansing, Michigan, United States, 48823
-
-
New York
-
Vestal, New York, United States, 13850
-
-
North Carolina
-
Denver, North Carolina, United States, 28037
-
-
Ohio
-
Powell, Ohio, United States, 43065
-
Springfield, Ohio, United States, 45503
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02888
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
-
-
Texas
-
Tyler, Texas, United States, 75701
-
-
Virginia
-
Salem, Virginia, United States, 24153
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subjects were required to have read, understand, and signed the Statement of Informed Consent and receive a fully executed copy of the form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Between 40 and 70 years of age.
- Subjects must own a wearable pair of spectacles, if required for their distance vision.
- Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration)
- Already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire"*
- The subject's vertex corrected spherical equivalent distance refraction was required to be in the range +3.50 to -5.75 in each eye.
- Refractive cylinder ≤ -0.75 D in each eye.
- ADD power in the range +0.75 D to +2.50 D in each eye.
- Best corrected visual acuity of 20/20-3 or better in each eye.
Exclusion Criteria:
- Currently pregnant or lactating (subjects who became pregnant during the study were discontinued).
- Any ocular or systemic allergies that may have contraindicated contact lens wear.
- Any ocular or systemic disease, autoimmune disease, or use of medication, that may have contraindicated contact lens wear.
- Any ocular abnormality that may have interfered with contact lens wear.
- Use of any ocular medication, with the exception of rewetting drops.
- Any previous intraocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
- History of herpetic keratitis.
- History of binocular vision abnormality or strabismus.
- Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV).
- History of diabetes.
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) which may contraindicate contact lens wear.
- Any ocular infection or inflammation.
- Any corneal distortion or irregular cornea.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: lotrafilcon B / etafilcon A
Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
|
Soft contact lens to be worn as daily wear, monthly replacement modality.
Other Names:
Soft contact lens to be worn as daily wear, daily disposable modality.
|
|
Experimental: etafilcon A / lotrafilcon B
Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
|
Soft contact lens to be worn as daily wear, monthly replacement modality.
Other Names:
Soft contact lens to be worn as daily wear, daily disposable modality.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Quality of Vision Using the Contact Lens User Experience (CLUE) TM Questionnaire
Time Frame: 8 -12 days post wear
|
CLUE Overall Quality of Vision is assessed using the Contact Lens User Experience (CLUE)TM questionnaire.
CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
97% of the scores fall within 0 and 120 (mean +/-3XSD).
|
8 -12 days post wear
|
|
Distance Binocular Visual Acuity (LogMAR)
Time Frame: 8- 12 Days post wear
|
Distance time controlled LogMAR Visual Acuity was carried out binocularly with high luminance and high contrast.
|
8- 12 Days post wear
|
|
Intermediate Binocular Visual Acuity (LogMAR)
Time Frame: 8-12 days post wear
|
Intermediate time controlled LogMAR Visual Acuity was carried out binocularly using High lumiance and High Contrast.
|
8-12 days post wear
|
|
Near Binocular Visual Acuity (LogMAR)
Time Frame: 8-12 days post wear
|
Near time controlled LogMAR Visual Acuity was carried out binocularly using High lumiance and High Contrast.
|
8-12 days post wear
|
|
Corneal Staining
Time Frame: 8 - 12 Days post wear
|
Corneal staining is evaluated using Sodium Fluorescein strips.
The Fluorescien strip was lightly placed on the subject's inferior palpebral conjunctiva.
The corneal Staining was graded using the scale Grade 0: No Staining, Grade 1: Trace(Minimal superficial staining or stippling), Grade 2: Mild (Regional or diffuse punctate staining), Grade 3:Moderate(Significant dense coalesced staining, corneal abrasion or foreign body tracks.),
Grade 4 Severe(Severe abrasions greater than 2 mm in diameter, ulcerations, epithelial loss, or full thickness abrasion.).
The data was dichotomized into two group subjects with grade 3 or higher staining, and those subjects with less than Grade 3. Below the percentage of subject eyes with grade 3 or higher is reported for each lens.
|
8 - 12 Days post wear
|
|
Bulbar Conjunctival Injection
Time Frame: 8- 12 Days post wear
|
The bulbar is the scelra.
Bulbar Conjunctival Injection was assessed using an Efron Grading scale by 1 unit increments.
Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4:Severe.
The data was dichotomized into two group subjects with grade 3 or higher Conjunctival injection, and those subjects with less than Grade 3. Below the percentage of subject eyes with grade 3 or higher is reported for each lens.
|
8- 12 Days post wear
|
|
Limbal Conjunctival Injection
Time Frame: 8- 12 Days post wear
|
The Limbus is the 1 to 2mm wide zone of conjunctiva and underlying tissue adjacent to where the cornea joins the sclera.
Limbal Conjunctival Injection was assesed using the Efron grading scale in 1 unit increments.
Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4:Severe.
The data was dichotomized into two group subjects with grade 3 or higher Conjunctival injection, and those subjects with less than Grade 3. Below the percentage of subject eyes with grade 3 or higher is reported for each lens.
|
8- 12 Days post wear
|
|
Contact Lens Fitting
Time Frame: 8- 12 Days post wear
|
Contact Lens fitting is reported as a binary response.
Yes- acceptable lens fit, No- unacceptable lens fit.
The percentage of subject eyes with acceptable fit is reported.
|
8- 12 Days post wear
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
August 20, 2014
First Submitted That Met QC Criteria
August 20, 2014
First Posted (Estimate)
August 22, 2014
Study Record Updates
Last Update Posted (Actual)
June 19, 2018
Last Update Submitted That Met QC Criteria
June 18, 2018
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-5593
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Ohio State UniversityRecruitingPresbyopia | Presbyopia CorrectionUnited States
-
Bruno Vision Careiuvo BioScience Operations, LLCCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
VIS, Inc.Active, not recruitingPresbyopia Correction
-
AST Products, Inc.CompletedCataract | Presbyopia CorrectionSpain
-
IROC AGAMO IrelandActive, not recruitingCataract | Presbyopia CorrectionSwitzerland
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
The Hong Kong Polytechnic UniversityNot yet recruitingPresbyopia | Presbyopia Correction
-
University Eye Hospital SvjetlostCompletedCataract | Visual Acuity | Presbyopia CorrectionCroatia
Clinical Trials on lotrafilcon B
-
Indiana UniversityAlcon ResearchCompleted
-
CIBA VISIONUniversity of WaterlooCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed
-
CooperVision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
CooperVision, Inc.Completed
-
CooperVision, Inc.Completed
-
CIBA VISIONCompleted